Table 2.

Small molecule kinase inhibitors presented in the current review and their associated infection complications.

Small molecule kinase inhibitor	Target	Main FDA-approved indications	Relative risk for infection	Predominant infection susceptibility
Ruxolitinib Tofacitinib Baricitinib	JAK1 JAK2 JAK3	Myelofibrosis, polycythemia vera, rheumatoid arthritis, inflammatory bowel disease, graft-versus-host disease	HIgh	Herpetic infections (common) > CMV disease, other opportunistic infections (mycobacteria, endemic fungi, aspergillosis)
Ibrutinib	BTK	Chronic lymphocytic leukemia, lymphomas, Waldenstrom macroglobulinemia, graft-versus-host disease	Intermediate	Bacterial infections (~5%); invasive fungal disease (~2–4% as monotherapy; 5–11% when combined with corticosteroids; >20% when combined with corticosteroids and chemotherapy); viral infections (~1%)
Dasatinib	BCR-ABL	Chronic myelogenous leukemia	High	Bacterial infections, CMV disease (HSCT), hepatitis B reactivation, Pneumocystis pneumonia
Idelalisib	PI3K (p100δ)	Chronic lymphocytic leukemia, lymphomas	High	CMV infection, Pneumocystis pneumonia
Fostamatinib	SYK	Immune thrombocytopenia	Unknown	Mucocutaneous fungal infections

CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation